Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results

Amgen is shrugging off a 14-year development alliance and the tens of millions of dollars spent to develop a new heart drug at Cytokinetics after a Phase III trial turned up weak data — leaving Cytokinetics to soldier on alone.